Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bridgett Foreman

Internal Medicine Alexandria, LA Medical Doctor

NPI 1902226285 CMS profile 1386495

176 Versailles Blvd, Alexandria, LA 71303

Open in the dashboard

General payments

$5,667

369 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bridgett Foreman of Alexandria, LA is reported in the CMS Open Payments database as having received $5,667 across 369 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,086 66
2024 General $1,269 82
2023 General $1,118 64
2022 General $773 53
2021 General $667 50
2020 General $383 26
2019 General $372 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bridgett Foreman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bridgett Foreman were reported at $1,086. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bridgett Foreman Internal Medicine median Middle half National median
2019 $372 $159 $48–$570 $163
2020 $383 $119 $33–$402 $114
2021 $667 $135 $37–$521 $132
2022 $773 $141 $42–$496 $149
2023 $1,118 $149 $45–$519 $160
2024 $1,269 $154 $47–$537 $164
2025 $1,086 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,021 146 payments
  2. Novo Nordisk Inc $818 57 payments
  3. Axsome Therapeutics, Inc. $453 28 payments
  4. Pfizer Inc. $326 23 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $254 13 payments
  6. Amgen Inc. $246 16 payments
  7. AstraZeneca Pharmaceuticals LP $210 13 payments
  8. Lilly USA, LLC $200 14 payments
  9. Otsuka America Pharmaceutical, Inc. $144 7 payments
  10. GlaxoSmithKline, LLC. $138 2 payments
  11. Other $856 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,667 369 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $1,077 75 payments
  2. UBRELVY $696 44 payments
  3. Ozempic $540 38 payments
  4. Auvelity $453 28 payments
  5. VRAYLAR $356 31 payments
  6. RYBELSUS $348 24 payments
  7. ELIQUIS $245 18 payments
  8. TRINTELLIX $223 11 payments
  9. Wegovy $171 11 payments
  10. REXULTI $144 7 payments
  11. Other $2,620 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

6,241

Median for Internal Medicine: 777

Drug cost

$515,442

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 134 $143,911
Jardiance Empagliflozin Brand 61 $59,452
Trulicity Dulaglutide Brand 24 $45,811
Mounjaro Tirzepatide Brand 30 $38,574
Januvia Sitagliptin Phosphate Brand 35 $34,196
Rybelsus Semaglutide Brand 28 $32,361
Eliquis Apixaban Brand 41 $30,445
Xarelto Rivaroxaban Brand 24 $26,016
Multaq Dronedarone Hcl Brand 12 $9,199
Farxiga Dapagliflozin Propanediol Brand 13 $7,319

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$114,101

Of which drugs: $60

Medicare patients

258

Average age 75

Services billed

3,858

196 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 62%
Ischemic heart disease 38%
Diabetes 36%
Depression 34%
Chronic kidney disease 28%
Osteoporosis 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 45 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $443
$443 — —
Auvelity
  • Axsome Therapeutics, Inc. $138
$138 — —
UBRELVY
  • AbbVie, Inc. $122
$122 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $105
$105 — —
VRAYLAR
  • AbbVie, Inc. $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record